CSL's largest blood products customer is the USA, its also its largest blood collection country. EU is (or was, don't quote me) the largest region for distribution of its flu vaccine, which it dominates the market by +70%. CSL are also extremely experienced at running successful P3 trials. So its not out of the relms if possibility.
That said, I agree its not a perfect match and a US big pharma would be a better suitor. However CSL could possibly be a better bodyguard to hostile takeover, if needed, than the "bank" that PR mentioned they would turn to in that situation.
Joint Venture, page-6
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $68.29M | |||
| Open | High | Low | Value | Volume |
| 19.5¢ | 20.5¢ | 19.0¢ | $156.2K | 795.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 152244 | 19.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 25584 | 1 |
View Market Depth
| Last trade - 16.10pm 01/10/2024 (20 minute delay) ? |
| PAR (ASX) Chart |